A randomized prospective controlled trial of oral acyclovir versus oral, ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients

Transplantation

Volumn 66, Issue 12, 1998, Pages 1682-1688

  Flechner, Stuart M ^a   Avery, Robin K ^a   Fisher, Rosemaree ^a   Mastroianni, Barbara A ^a   Papajcik, Dorren A ^a   O'Malley, Kiaran J ^a   Goormastic, Marlene ^a   Goldfarb, David A ^a   Modlin, Charles S ^a   Novick, Andrew C ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; GANCICLOVIR; IMMUNOGLOBULIN;

ADULT; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GRAFT REJECTION; HUMAN; INFECTION RATE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROPHYLAXIS; VIRUS ISOLATION;

ACUTE DISEASE; ACYCLOVIR; ADMINISTRATION, ORAL; ADULT; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; GRAFT REJECTION; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULINS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 0032573740     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199812270-00019     Document Type: Article

References (39)

1. Rubin RH. Infection in the organ transplant recipient. In: Rubin RH, Young LS, eds. Clinical approach to infection in the compromised host. New York: Plenum Medical Book, 1994; 629.
2. Patel R, Snydman DR, Rubin RH, et al. Cytomegalovirus prophylaxis in solid organ transplant recipients. Transplantation 1996; 61: 1279.
3. Rubin RH. Impact of cytomegalovirus infection on organ transplant recipients. Rev Infect Dis 1990; 12(Suppl 7): S754.
4. McCarthy JM, Karim MA, Keown PA. The cost impact of cytomegalovirus disease in renal transplant recipients. Transplantation 1993; 55: 1277.
5. Gorensek MJ, Stewart RW, Keys TF, et al. Symptomatic cytomegalovirus infection as a significant risk factor for major infections after cardiac transplantation. J Infect Dis 1988; 158: 884.
6. George MJ, Syndman DR, Werner BG, et al. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in othotopic liver transplant recipients. Am J Med 1997; 103: 102.
7. Pouteil-Noble C, Ecochard R, Landrivon G, et al. Cytomegalovirus infection: an etiological factor for rejection? A prospective study in 242 renal transplant patients. Transplantation 1993; 55: 851.
8. Reinke P, Tietze E, Ode-Hakim S, et al. Late acute renal allograft rejection and symptomless cytomegalovirus infection. Lancet 1994; 344: 1737.
9. Hibberd PL, Tolkoff-Rubin NE, Cosimi AB, et al. Symptomatic cytomegalovirus disease in cytomegalovirus antibody seropositive renal transplant recipients treated with OKT3. Transplantation 1992; 53: 68.
10. Bailey TC, Powderly WG, Stortch GA, et al. Symptomatic cytomegalovirus infection in renal transplant recipients given either Minnesota antilymphoblast globulin (MALG) or OKT3 for rejection prophylaxis. Am J Kidney Dis 1993; 21: 196.
11. Snydman DR, Werner BG, Heinze-Lacey B, et al. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal transplant recipients. New Engl J Med 1987; 317: 1049.
12. Balfour HH, Chace BA, Stapleton JT, et al. A randomized placebo controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. New Engl J Med 1989; 320: 1381.
13. Nicol DL, MacDonald AS, Belitsky P, et al. Reduction by combination prophylactic therapy with CMV hyperimmune globulin and acyclovir of the risk of primary CMV disease in renal transplant recipients. Transplantation 1993; 55: 841.
14. Hibberd PL, Tolkoff-Rubin NE, Conti D, et al. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in anti-body positive renal transplant recipients. Ann Int Med 1995; 123: 39.
15. Badley AD, Seaberg EC, Porayko MK, et al. Prophylaxis of cytomegalovirus infection in liver transplantation: a randomized trial comparing a combination of ganciclovir and acyclovir to acyclovir. Transplantation 1997; 64: 66.
16. Spector SA, Busch DF, Follansbee S, et al. Pharmacokinetic, safety, antiviral profiles of oral ganciclovir in persons infected with human immunodeficiency virus: a phase I/II study. AIDS Clinical Trials Group, and Cytomegalovirus Cooperative Study Group. J Infect Dis 1995; 171: 1431.
17. Anderson RD, Griffey KG, Jung D, et al. Ganciclovir absolute bioavailability and steady state pharmacokinetics after oral administration of two 3000 mg/d dosing regimens in HIV and CMV seropositive patients. Clin Ther 1995; 17: 425.
18. Spector SA, Busch DF, Follansbee S, et al. Oral ganciclovir for the prevention of cytomegalovirus disease in patients with AIDS. New Engl J Med 1996; 334: 1491.
19. Drew WL, Ives D, Lalezari JP, et al. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. New Engl J Med 1995; 333: 615.
20. Brennan DC, Garlock KA, Singer GG, et al. Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients. Transplantation 1997; 64: 1843.
21. Ahsan N, Holman MJ, Yang HC. Efficacy of oral ganciclovir in prevention of cytomegalovirus infection in post kidney transplant patients. Clin Transplant 1997; 11: 633.
22. Gane G, Saliba F, Valdecasas GJC, et al. Randomized trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver transplant recipients. Lancet 1997; 350: 1729.
23. Page CV, Wold AV, Smith TF. Detection of CMV infections in specimens other than urine by the shell vial assay and conventional tube cell culture. J Clin Microbiol 1987; 25: 755.
24. Mazzulli T, Wood S, Chua R, Walmsley S. Evaluation of the Digene Hybrid Capture system for detection and quantitation of human CMV viremia in HIV infected patients. J Clin Microbiol 1996; 34: 2959.
25. Wilcoxon F. Individual comparisons by ranking methods. Boimetrics Bulletin 1955; 1: 80.
26. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457.
27. Peto R, Peto J. Asymptomatically efficient rank invariant test procedures. J Roy Stat Soc 1972; 135: 185.
28. Cox DR. Regression models and life tables. J R Stat Soc 1972; 34: 187.
29. Flechner SM, Novick AC, Steinmuller D. Improved cadaver allograft survival in transfused recipients who remain serologically negative for cytomegalovirus. J Urol 1982; 127: 644.
30. Bailey TC, Ettinger NA, Storch GA, et al. Failure of high dose acyclovir with or without immune globulin to prevent primary CMV disease in recipients of solid organ transplants. Am J Med 1993; 95: 274.
31. Kletzmayr J, Kotzmann H, Kovarik J, et al. Impact of high dose oral acyclovir prophylaxis on CMV disease in CMV high risk renal transplant recipients. J Am Soc Nephrol 1996; 7: 325.
32. Goral S, Ynares C, Dummer S, Helderman J. Acyclovir prophylaxiis for cytomegalovirus disease in high risk renal transplant recipients: is it effective? Kidney Int 1996; 50: S62.
33. Lowance D, Legendre C, Neumayer H, et al. Valacyclovir reduces the incidence of CMV disease and acute graft rejection in CMV seronegative recipients of a seropositive cadaveric renal allograft. American Society of Transplant Physicians 17th Annual Meeting, May 9-13, 1998, Chicago, IL.
34. US Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60: 225.
35. Kahan BD. Sirolimus: a new agent for clinical renal transplantation. Transplant Proc 1997; 29: 48.
36. Vincenti F, Kirkman R, Light S, et al., for the Daclizumab triple therapy study group. Interleukin-2 receptor blockade with daclizumab to prevent acute rejection in renal transplantation. New Engl J Med 1998; 338: 161.
37. Nashan B, Moore R, Amlot P, et al., for the CHIB 201 International Study Group. Randomized trial of basiliximab vs. placebo for control of acute cellular rejection in renal allograft recipients. Lancet 1997; 350: 1193.
38. Reusser P, Cordonnier C, Einsele H, et al. European survey of herpes virus resistance to anti-viral drugs in bone marrow transplant recipients. Bone Marrow Transplant 1996; 17: 813.
39. Rosen HR, Benner KG, Flora KD, et al. Development of ganciclovir resistance during treatment of primary cytomegalovirus infection after liver transplantation. Transplantation 1997; 63: 476.